Coverage and Reimbursement Challenges and Strategies: Module 8 of 12

REGISTER HERE
aci17-sitc-clr.jpg

It is important to note there are twelve ACI online modules, you are currently reviewing module eight. You may complete any of the modules in the order you choose. Each module can be completed independently for continuing education credit. 


The Coverage and Reimbursement Challenges and Strategies module covers applicable immunotherapy coverage challenges, reviews real-world case studies, and identifies solutions for specific immunotherapy scenarios including: predetermination, denials/uninsured patients, appeals process and medication assistance methods.

Module 8

Sigrun Hallmeyer, MD – Advocate Medical Group

Educational Objectives

  • Identify applicable immunotherapy coverage challenges
  • Identify solutions for specific immunotherapy scenarios including predetermination, denials/uninsured patients, appeals process, etc
  • Outline how to establish medical necessity, missing pre-certification and/or new agents

Target Audience

The ACI 2017 video series have been designed to meet the educational needs of physicians, pharmacists, registered nurses and other healthcare professionals involved in the care of patients with cancer.

Related Class Content

All modules offer Continuing Education (CE) Credit

Register/Access Class

Target Audience
Clinician Icon

Credit Available
Oct. 6, 2017- Sept. 30, 2018

Credits
  • CME: 0.75 AMA PRA Category 1 Credit(s)™
  • CNE: 0.7 contact hours
  • CPE: 0.75 contact hours (0.075 CEUs)

Approximate Time to Complete
0.5 hours

Cost
Free

Please use one of the following Internet browsers to open this activity: Chrome, Firefox, or Safari browsers in order to view this online activity.

Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer 

The 2017 Advances in Cancer Immunotherapy™ series is supported in part by independent medical educational grants from 
Aduro Biotech, Inc., Amgen, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb, Merck & Co., Inc. and Prometheus Laboratories Inc.